Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors.
Ping ChiLi-Xuan QinNiedzica CamachoCiara M KellySandra P D'AngeloMark A DicksonMrinal M GounderMary L KeohanSujana MovvaBenjamin A NacevEvan RosenbaumKatherine A ThorntonAimee M CragoJasmine H FrancisMoriah MartindaleHaley T PhelanMatthew D BiniakewitzCindy J LeeSamuel SingerSinchun HwangMichael F BergerJuliet ChenCristina R AntonescuWilliam D TapPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The combination of imatinib and binimetinib is safe with manageable toxicity and has encouraging activity in SDH-deficient but not imatinib-refractory KIT/PDGFRA-mutant GISTs. The observed clinical benefits provide a motivation for a larger trial of the combination strategy in SDH-deficient GISTs.